Skip to main content

Advertisement

SpringerLink
Log in

ASO Author Reflections: Predicting High-Risk Oncotype DX Recurrence Scores as a Strategy for Assessing Neoadjuvant Chemotherapy Eligibility

  • ASO Author Reflections
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164–72.

    Article  Google Scholar 

  2. Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379:111–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Sparano JA, Gray RJ, Makower DF, et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med. 2015;373:2005–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Park KU, Chen Y, Chitale D, et al. Utilization of the 21-gene recurrence score in a diverse breast cancer patient population: development of a clinicopathologic model to predict high-risk scores and response to neoadjuvant chemotherapy. Ann Surg Oncol. 2018;25:1921–7.

    Article  PubMed  Google Scholar 

  5. Farrugia DJ, Landmann A, Zhu L, et al. Magee equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor-positive, HER2-negative/equivocal breast tumors. Mod Pathol. 2017;30:1078–85.

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosures

There are no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Surgery, Weill Cornell Medicine, New York, NY, USA

    Lisa Newman MD, MPH

Authors
  1. Lisa Newman MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lisa Newman MD, MPH.

Additional information

ASO Author Reflections offer a brief invited commentary on the article “Utilization of the 21-Gene Recurrence Score in a Diverse Breast Cancer Patient Population: Development of a Clinicopathologic Model to Predict High-Risk Scores and Response to Neoadjuvant Chemotherapy”. Ann Surg Oncol. 2018;25:1921–7.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Newman, L. ASO Author Reflections: Predicting High-Risk Oncotype DX Recurrence Scores as a Strategy for Assessing Neoadjuvant Chemotherapy Eligibility. Ann Surg Oncol 25 (Suppl 3), 683–684 (2018). https://doi.org/10.1245/s10434-018-6989-1

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-018-6989-1

Keywords

Search

Navigation